The House Committee on Energy and Commerce Subcommittee on Health announced a hearing this week to discuss legislation to improve the 340B Drug Pricing Program.
The July 11 hearing will include testimony from two essential hospital leaders: Fred Cerise, MD, MPH, president and CEO of Parkland Health & Hospital System, and Charles Daniels, PhD, BS Pharm, pharmacist-in-chief and associate dean of the University of California-San Diego. Other witnesses include Debra Patt, MD, MPH, MBA, vice president of public policy and academic affairs of Texas Oncology, and Debra Draper, PhD, MSHA, director of health care at the Government Accountability Office (GAO).
The hearing will focus first on the latest GAO report on 340B contract pharmacies and then move on to focus on program stakeholders. The committee also released a list of 15 bills and discussion drafts for debate at the hearing.
America’s Essential Hospitals issued an Action Alert with more information on the bills that will be discussed in the hearing. The association urges members to reach out to their representatives on the committee and encourage them to support several of the bills aimed at protecting the program.